{
    "2020-08-05": [
        [
            {
                "time": "2023-10-05",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Moderna",
                        "Pfizer",
                        "Sanofi",
                        "GlaxoSmithKline",
                        "BioNTech"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes",
                "features": {
                    "keywords": [
                        "Empagliflozin",
                        "Phase III",
                        "cardiovascular",
                        "diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "NIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 cases",
                "features": {
                    "keywords": [
                        "NIH",
                        "Lilly",
                        "monoclonal antibody",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}